CN118302199A - 抗cdh6抗体及其抗体-药物偶联物 - Google Patents

抗cdh6抗体及其抗体-药物偶联物 Download PDF

Info

Publication number
CN118302199A
CN118302199A CN202280076590.9A CN202280076590A CN118302199A CN 118302199 A CN118302199 A CN 118302199A CN 202280076590 A CN202280076590 A CN 202280076590A CN 118302199 A CN118302199 A CN 118302199A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280076590.9A
Other languages
English (en)
Chinese (zh)
Inventor
孟逊
刘淑惠
史静
王明桥
潘荣
蒋岳云
王一强
王朝晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Original Assignee
Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2021/136994 external-priority patent/WO2023102875A1/en
Application filed by Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd filed Critical Puzhong Discovery Pharmaceutical Technology Shanghai Co ltd
Publication of CN118302199A publication Critical patent/CN118302199A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280076590.9A 2021-12-10 2022-12-09 抗cdh6抗体及其抗体-药物偶联物 Pending CN118302199A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2021/136994 WO2023102875A1 (en) 2021-12-10 2021-12-10 Anti-cdh6 antibody drug conjugate
CNPCT/CN2021/136994 2021-12-10
CN202111507685 2021-12-10
CN202111507685.5 2021-12-10
PCT/CN2022/137932 WO2023104188A1 (en) 2021-12-10 2022-12-09 Anti-cdh6 antibodies and antibody-drug conjugates thereof

Publications (1)

Publication Number Publication Date
CN118302199A true CN118302199A (zh) 2024-07-05

Family

ID=86729685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280076590.9A Pending CN118302199A (zh) 2021-12-10 2022-12-09 抗cdh6抗体及其抗体-药物偶联物

Country Status (11)

Country Link
US (1) US20250090677A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444360A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024545170A (cg-RX-API-DMAC7.html)
KR (1) KR20240130160A (cg-RX-API-DMAC7.html)
CN (1) CN118302199A (cg-RX-API-DMAC7.html)
AU (1) AU2022406708A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239715A1 (cg-RX-API-DMAC7.html)
IL (1) IL313227A (cg-RX-API-DMAC7.html)
MX (1) MX2024007035A (cg-RX-API-DMAC7.html)
TW (1) TW202330618A (cg-RX-API-DMAC7.html)
WO (1) WO2023104188A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026082031A1 (zh) * 2024-10-14 2026-04-23 先声再明医药股份有限公司 一种包含抗cdh6抗体或其adc的药物组合物
WO2026130458A1 (zh) * 2024-12-19 2026-06-25 上海齐鲁制药研究中心有限公司 一种抗cdh6抗体、其偶联物及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238440A1 (en) * 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
AU2024236246A1 (en) 2023-03-14 2025-10-30 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor
JPWO2024204679A1 (cg-RX-API-DMAC7.html) 2023-03-31 2024-10-03
WO2026120507A1 (en) 2024-12-04 2026-06-11 Daiichi Sankyo Company, Limited An antibody-drug conjugate for use in the treatment of drug-resistant cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017001946A (es) * 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
US10829560B2 (en) * 2015-04-20 2020-11-10 Consejo Superior De Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
WO2018185618A1 (en) * 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TWI926682B (zh) * 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CA3119956A1 (en) * 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026082031A1 (zh) * 2024-10-14 2026-04-23 先声再明医药股份有限公司 一种包含抗cdh6抗体或其adc的药物组合物
WO2026130458A1 (zh) * 2024-12-19 2026-06-25 上海齐鲁制药研究中心有限公司 一种抗cdh6抗体、其偶联物及其应用

Also Published As

Publication number Publication date
AU2022406708A1 (en) 2024-06-27
MX2024007035A (es) 2024-06-21
TW202330618A (zh) 2023-08-01
CA3239715A1 (en) 2023-06-15
EP4444360A4 (en) 2026-06-17
JP2024545170A (ja) 2024-12-05
WO2023104188A1 (en) 2023-06-15
IL313227A (en) 2024-07-01
KR20240130160A (ko) 2024-08-28
EP4444360A1 (en) 2024-10-16
US20250090677A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
EP4410372A1 (en) Antibody, antibody-drug conjugate thereof and use thereof
WO2023102875A1 (en) Anti-cdh6 antibody drug conjugate
EP3307274B1 (en) Anti-cd123 antibodies and conjugates thereof
WO2023104188A1 (en) Anti-cdh6 antibodies and antibody-drug conjugates thereof
KR102881140B1 (ko) 항-her2 항체-약물 접합체
CN110575547B (zh) 靶向于tf的抗体-药物偶联物及其制法和用途
CN110903395A (zh) 抗体、偶联物及其制备方法和用途
CN111378041A (zh) 抗-egfr抗体及抗体药物偶联物
CN117693526A (zh) 抗-c-Met抗体药物缀合物
CA3005294A1 (en) Anti-5t4 antibodies and antibody-drug conjugates
CN114904015A (zh) 包含抗cldn18.2的抗体或其抗原结合片段的抗体药物偶联物及其用途
CN110575548A (zh) 靶向于cd73的抗体-药物偶联物及其制法和用途
WO2024240227A1 (en) Antibodies and antibody-drug conjugates thereof
KR20240099178A (ko) 항 cd37 항체-약물 콘주게이트
JP2025523605A (ja) 抗fgfr3抗体コンジュゲート及びその医療用途
WO2025157214A1 (zh) 抗FGFR2b抗体及抗体药物偶联物
HK40107995A (en) Anti-cdh6 antibodies and antibody-drug conjugates thereof
CN121868507A (zh) 抗EGFR和cMET双特异性抗体的抗体药物偶联物
CA3300455A1 (en) Antibody-drug conjugate having high drug load and use thereof
HK40117137A (en) Anti-fgfr3 antibody conjugate and medical use thereof
WO2025199464A1 (en) Anti-trop2 antibody-drug conjugates and methods of use
AU2024269443A1 (en) Anti-epidermal growth factor receptor (egfr) antibody-drug conjugate and use thereof
TW202540177A (zh) 抗-FGFR2b免疫偶聯物及其於治療癌症的用途
HK1253305B (en) Anti-cd123 antibodies and conjugates thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: Unit 10, 159 Tianzhou Road, Xuhui District, Shanghai, 200233

Applicant after: Puzhong discovery Pharmaceutical Technology (Shanghai) Co.,Ltd.

Address before: 200233 floor 3, building 1, No. 333, Guiping Road, Xuhui District, Shanghai

Applicant before: Puzhong discovery Pharmaceutical Technology (Shanghai) Co.,Ltd.

Country or region before: China

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Meng Xun

Inventor after: Liu Shuhui

Inventor after: Shi Jing

Inventor before: Meng Xun

Inventor before: Liu Shuhui

Inventor before: Shi Jing

Inventor before: Wang Mingqiao

Inventor before: Pan Rong

Inventor before: Jiang Yueyun

Inventor before: Wang Yiqiang

Inventor before: Wang Chaohui

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107995

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: Unit 10, 159 Tianzhou Road, Xuhui District, Shanghai, 200233

Applicant after: Puzhong Discovery Pharmaceutical Technology (Shanghai) Co.,Ltd.

Address before: Unit 10, 159 Tianzhou Road, Xuhui District, Shanghai, 200233

Applicant before: Puzhong discovery Pharmaceutical Technology (Shanghai) Co.,Ltd.

Country or region before: China